Skip to main content

Advertisement

SpringerLink
Log in

A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Streptococcus pneumoniae is an important pathogen accounting for a large number of deaths worldwide. Despite the multitude of capsular polysaccharide vaccines used to guard against pneumococcal disease, fatal pneumococcal disease remains epidemic due to the narrow range of protection afforded by the capsular polysaccharide vaccines and rate of change in serotypes. The most promising solution is to develop an improved protein-based vaccine with broad protection. In this study, we tested a bivalent vaccine containing antigens mixed with the fusion protein PsaA-pneumococcal surface protein A (PspA)23 and single protein PspA4, including conserved PsaA and PspA from clades 2, 3, and 4 with coverage for families 1 and 2. The vaccine induced a significant increase of anti-PspA IgG, which demonstrated cross-reactivity with the 22 different S. pneumoniae strains from serotypes contained in PPV23 by Western blot. The wide ranging protection was determined by challenging mice with S. pneumoniae from PspA clades 1 to 5. Bacterial loads in the blood and lung and survival rate after challenge were measured. After immunization, the number of bacteria in mice was significantly reduced. The clearance rates with all strains were greater than 90% in the lung, and bacterial loads in the blood were decreased to lower than 10 CFU/ml. The survival rates in immunized animals also were greatly increased (all over 50%) compared with controls. Therefore, this bivalent PspA vaccine may be a good substitute for capsular polysaccharide vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25–32.

    Article  PubMed  Google Scholar 

  2. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol. 2006;32:139–53.

    Article  PubMed  CAS  Google Scholar 

  3. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.

    Article  PubMed  Google Scholar 

  4. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–95.

    Article  PubMed  CAS  Google Scholar 

  5. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine. 1999;17 Suppl 1:S79–84.

  6. Miyaji EN, Oliveira ML, Carvalho E, Ho PL. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70:3303–26.

    Article  PubMed  CAS  Google Scholar 

  7. Zhu F, Hu Y, Li J, Ye Q, Young MM Jr, Zhou X, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine compared with 7-valent pneumococcal conjugate vaccine among healthy infants in China. Pediatr Infect Dis J. 2016;35:999–1010.

  8. Weil OC. Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children. Med Mal Infect. 2013;43:309–21.

    Article  Google Scholar 

  9. Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine. 2011;29(Suppl 3):C43–8.

    Article  PubMed  Google Scholar 

  10. Pandya GA, McEllistrem MC, Venepally P, Holmes MH, Jarrahi B, Sanka R, et al. Monitoring the long-term molecular epidemiology of the pneumococcus and detection of potential ‘vaccine escape’ strains. PLoS One. 2011;6:e15950.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Mukerji R, Mirza S, Roche AM, Widener RW, Croney CM, Rhee DK, et al. Pneumococcal surface protein a inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol. 2012;189:5327–35.

  12. Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol. 2012;19:1574–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Roche H, Hakansson A, Hollingshead SK, Briles DE. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun. 2003;71:1033–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Susan K, Hollingshead RB, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun. 2000;68:5889–900.

    Article  Google Scholar 

  15. Briles DE, Hollingshead SK, Swift A, Braun PA, Ferguson LM, Nabors GS, et al. Immunization of humans with recombinant pneumococcal surface protein a (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis. 2000;182:1694–701.

    Article  PubMed  CAS  Google Scholar 

  16. Darrieux M, Goulart C, Briles D, Leite LC. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol. 2015;41:190–200.

    Article  PubMed  CAS  Google Scholar 

  17. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001;69:6718–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol. 2010;17:439–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, et al. Protective immune responses elicited by fusion protein containing PsaA and PspA fragments. Immunol Investig. 2015;44:482–96.

  20. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One. 2010;5:1–14.

    Google Scholar 

  21. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001;65:187–207. first page, table of contents

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Melin MM, Hollingshead SK, Briles DE, Lahdenkari MI, Kilpi TM, Kayhty HM. Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae. Clin Vaccine Immunol. 2008;15:1529–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol. 2008;57:273–8.

    Article  PubMed  CAS  Google Scholar 

  24. Piao Z, Akeda Y, Takeuchi D, Ishii KJ, Ubukata K, Briles DE, et al. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice. Vaccine. 2014;32:5607–13.

    Article  PubMed  CAS  Google Scholar 

  25. Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, et al. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun. 2007;75:5930–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Thi Sarkis for the editorial support in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, 130012, China

    Jinfei Yu, Xiaorui Chen, Bo Li, Tiejun Gu, Xiangyu Meng, Wei Kong & Yongge Wu

Authors
  1. Jinfei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaorui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tiejun Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiangyu Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yongge Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongge Wu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, J., Chen, X., Li, B. et al. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains. Immunol Res 66, 528–536 (2018). https://doi.org/10.1007/s12026-018-9016-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-018-9016-5

Keywords

Search

Navigation